Tags

Type your tag names separated by a space and hit enter

Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.
J Bone Miner Res. 2014 Dec; 29(12):2545-51.JB

Abstract

Minimizing post-fracture bone loss is an important aspect of recovery from hip fracture, and determination of factors that affect bone mineral density (BMD) response to treatment after hip fracture may assist in the development of targeted therapeutic interventions. A post hoc analysis of the HORIZON Recurrent Fracture Trial was done to determine the effect of zoledronic acid (ZOL) on total hip (TH) and femoral neck (FN) BMD in subgroups with low-trauma hip fracture. A total of 2127 patients were randomized (1:1) to yearly infusions of ZOL 5 mg (n = 1065) or placebo (n = 1062) within 90 days of operation for low-trauma hip fracture. The 1486 patients with a baseline and at least one post-baseline BMD assessment at TH or FN (ZOL = 745, placebo = 741) were included in the analyses. Percentage change from baseline in TH and FN BMD was assessed at months 12 and 24 and compared across subgroups of hip fracture patients. Percentage change from baseline in TH and FN BMD at months 12 and 24 was greater (p < 0.05) in ZOL-treated patients compared with placebo in most subgroups. Treatment-by-subgroup interactions (p < 0.05) indicated that a greater effect on BMD was observed for TH BMD at month 12 in females, in patients in the lower tertile body mass index at baseline (≤22.6 kg/m(2)), and in patients with baseline FN BMD T-score of ≤ -2.5; for FN BMD in patients who received ZOL for >6 weeks post-surgery; and for TH and FN BMD in patients with a history of one or more prior fractures. All interactions were limited to the first 12 months after treatment with none observed for the 24-month comparisons. (Clinical trial registration number NCT00046254.)

Authors+Show Affiliations

University of Maryland, Baltimore, MD, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24839241

Citation

Magaziner, Jay S., et al. "Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, vol. 29, no. 12, 2014, pp. 2545-51.
Magaziner JS, Orwig DL, Lyles KW, et al. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. J Bone Miner Res. 2014;29(12):2545-51.
Magaziner, J. S., Orwig, D. L., Lyles, K. W., Nordsletten, L., Boonen, S., Adachi, J. D., Recknor, C., Colón-Emeric, C. S., Mesenbrink, P., Bucci-Rechtweg, C., Su, G., Johnson, R., & Pieper, C. F. (2014). Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 29(12), 2545-51. https://doi.org/10.1002/jbmr.2283
Magaziner JS, et al. Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture. J Bone Miner Res. 2014;29(12):2545-51. PubMed PMID: 24839241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. AU - Magaziner,Jay S, AU - Orwig,Denise L, AU - Lyles,Kenneth W, AU - Nordsletten,Lars, AU - Boonen,Steven, AU - Adachi,Jonathan D, AU - Recknor,Chris, AU - Colón-Emeric,Cathleen S, AU - Mesenbrink,Peter, AU - Bucci-Rechtweg,Christina, AU - Su,Guoqin, AU - Johnson,Rasheeda, AU - Pieper,Carl F, PY - 2014/01/28/received PY - 2014/05/02/revised PY - 2014/05/05/accepted PY - 2014/5/20/entrez PY - 2014/5/20/pubmed PY - 2015/7/15/medline KW - ANTIRESORPTIVES KW - CLINICAL TRIALS KW - FRACTURE PREVENTION KW - INJURY/FRACTURE HEALING KW - OSTEOPOROSIS SP - 2545 EP - 51 JF - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JO - J Bone Miner Res VL - 29 IS - 12 N2 - Minimizing post-fracture bone loss is an important aspect of recovery from hip fracture, and determination of factors that affect bone mineral density (BMD) response to treatment after hip fracture may assist in the development of targeted therapeutic interventions. A post hoc analysis of the HORIZON Recurrent Fracture Trial was done to determine the effect of zoledronic acid (ZOL) on total hip (TH) and femoral neck (FN) BMD in subgroups with low-trauma hip fracture. A total of 2127 patients were randomized (1:1) to yearly infusions of ZOL 5 mg (n = 1065) or placebo (n = 1062) within 90 days of operation for low-trauma hip fracture. The 1486 patients with a baseline and at least one post-baseline BMD assessment at TH or FN (ZOL = 745, placebo = 741) were included in the analyses. Percentage change from baseline in TH and FN BMD was assessed at months 12 and 24 and compared across subgroups of hip fracture patients. Percentage change from baseline in TH and FN BMD at months 12 and 24 was greater (p < 0.05) in ZOL-treated patients compared with placebo in most subgroups. Treatment-by-subgroup interactions (p < 0.05) indicated that a greater effect on BMD was observed for TH BMD at month 12 in females, in patients in the lower tertile body mass index at baseline (≤22.6 kg/m(2)), and in patients with baseline FN BMD T-score of ≤ -2.5; for FN BMD in patients who received ZOL for >6 weeks post-surgery; and for TH and FN BMD in patients with a history of one or more prior fractures. All interactions were limited to the first 12 months after treatment with none observed for the 24-month comparisons. (Clinical trial registration number NCT00046254.) SN - 1523-4681 UR - https://www.unboundmedicine.com/medline/citation/24839241/Subgroup_variations_in_bone_mineral_density_response_to_zoledronic_acid_after_hip_fracture_ L2 - https://doi.org/10.1002/jbmr.2283 DB - PRIME DP - Unbound Medicine ER -